Market Newsdesk

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical Products Administration (“NMPA”) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (“ICC”) with fibroblast growth factor receptor (“FGFR”) 2 fusion or rearrangement who have previously received systemic therapy. Fanregratinib will be marketed in China under the brand name ATLED^®. 

ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2-15.0% of primary liver cancers, and consequently it is the second most common type after hepatocellular carcinoma. In recent years, the incidence of ICC has continued to rise, with a 5-year overall survival rate of approximately 9%.¹ Approximately 10-15% of ICC patients globally have tumors harboring FGFR2 fusions or rearrangements.^2,3

The approval is supported by data from the Phase II registration cohort of the single-arm, multi-center, open-label, pivotal Phase II/IIIb clinical trial of ATLED^® in China (NCT04353375). The results were recently presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2026. The study met its primary endpoint, demonstrating an Independent Review Committee (IRC)-assessed objective response rate (ORR) of 42.5% (95% CI: 30.0%–53.6%) in pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements, representing a strong, clinically meaningful response.

Key secondary endpoints showed consistent clinical activity and a rapid onset of action, with a median time to response of 1.4 months. Median duration of response (DoR) was 6.9 months (95% CI: 5.6–8.5) and disease control rate (DCR) reached 83.9% (95% CI: 74.5%–90.9%). Furthermore, the median progression-free survival (PFS) was 6.9 months (95% CI: 4.1–8.2), while the median overall survival (OS) was 16.6 months (95% CI: 12.4–16.6).

“As a major and devastating subtype of primary liver cancer, intrahepatic cholangiocarcinoma carries an immense disease burden with historically limited targeted options. We are thrilled by the NMPA approval of ATLED^®, which directly addresses this critical therapeutic gap in China,” said Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED. “This approval unlocks an important new treatment alternative for a substantial population of pretreated advanced ICC patients. We are fully prepared to leverage our established commercial infrastructure to bring this precision medicine to patients as rapidly as possible.”

The Phase IIIb portion of the trial will serve as the confirmatory study to further validate the clinical benefits and safety of ATLED^® in this setting. Enrollment for this confirmatory cohort was initiated in January 2026.

About ATLED

^®

ATLED^® (fanregratinib, HMPL-453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of fanregratinib, the further clinical development for fanregratinib, its expectations as to whether any studies on fanregratinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fanregratinib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in other jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of fanregratinib for a targeted indication; and HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for fanregratinib, and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / [email protected]
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / [email protected]
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / [email protected]
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

_____________________________
REFERENCES

1	Expert consensus on precision detection of intrahepatic cholangiocarcinoma (2024 edition). Chin J Clin Med. 2025;32(1):1-18.
2	Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–34.
3	Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–10.

SHANGHAI, Aug. 27, 2026 (GLOBE NEWSWIRE) — FinVolution Group (“FinVolution” or the “Company”) (NYSE: FINV), a leading fintech platform across China and overseas markets, today announced its unaudited financial results for the second quarter ended June 30, 2026.

	For the Three Months Ended/As of		YoY Change
	June 30, 2025	June 30, 2026
Total Transaction Volume (RMB in billions) 1	54.0	44.8	-17.0%
– Chinese Mainland2	50.8	41.0	-19.3%
– Overseas Markets3	3.2	3.8	18.8%
Total Outstanding Loan Balance (RMB in billions)	77.5	67.9	-12.4%
– Chinese Mainland4	75.4	65.4	-13.3%
– Overseas Markets5	2.1	2.5	19.0%

Second Quarter 2026 Highlights

Chinese Mainland Market

• Cumulative registered users reached 192.8 million as of June 30, 2026, an increase of 6.6% compared with June 30, 2025.
• Cumulative borrowers reached 30.1 million as of June 30, 2026, an increase of 7.9% compared with June 30, 2025.
• Number of unique borrowers⁶ for the second quarter of 2026 was 1.8 million, a decrease of 18.2% compared with the same period of 2025.
• Transaction volume² was RMB41.0 billion for the second quarter of 2026, a decrease of 19.3% compared with the same period of 2025.
• Transaction volume facilitated for repeat individual borrowers⁷ for the second quarter of 2026 was RMB34.8 billion, a decrease of 20.5% compared with the same period of 2025.
• Outstanding loan balance⁴ was RMB65.4 billion as of June 30, 2026, a decrease of 13.3% compared with June 30, 2025.
• Average loan size was RMB10,742 for the second quarter of 2026, compared with RMB10,056 for the same period of 2025.
• Average loan tenure was 8.5 months for the second quarter of 2026, compared with 8.3 months for the same period of 2025.
• 90 day+ delinquency ratio⁸ was 2.10% as of June 30, 2026.
• Net revenue⁹ was RMB2,396.7 million (US$353.2 million) for the second quarter of 2026, compared with RMB2,781.3 million for the same period of 2025.
• U.S. GAAP operating profit¹⁰ was RMB624.8 million (US$92.1 million) for the second quarter of 2026, compared with RMB913.6 million for the same period of 2025.
• Non-GAAP adjusted EBITDA¹¹, which excludes depreciation and amortization and share-based compensation expenses from operating profit, was RMB641.9 million (US$94.6 million) for the second quarter of 2026, compared with RMB930.6 million for the same period of 2025.

Overseas Markets

• Cumulative registered users reached 61.4 million as of June 30, 2026, an increase of 43.5% compared with June 30, 2025.
• Cumulative borrowers reached 15.6 million as of June 30, 2026, an increase of 79.3% compared with June 30, 2025.
• Number of unique borrowers¹² for the second quarter of 2026 was 5.3 million, an increase of 130.4% compared with the same period of 2025.
• Number of new borrowers¹³ for the second quarter of 2026 was 2.2 million, an increase of 100.0% compared with the same period of 2025.
• Transaction volume³ reached RMB3.8 billion for the second quarter of 2026, an increase of 18.8% compared with the same period of 2025.
• Outstanding loan balance⁵ reached RMB2.5 billion as of June 30, 2026, an increase of 19.0% compared with June 30, 2025.
• Net revenue¹⁴ was RMB930.3 million (US$137.1 million) for the second quarter of 2026, an increase of 18.0% compared with the same period of 2025, representing 27.3% of total revenue for the second quarter of 2026.
• U.S. GAAP operating profit¹⁰ was RMB53.6 million (US$7.9 million) for the second quarter of 2026, compared with RMB25.6 million for the same period of 2025.
• Non-GAAP adjusted EBITDA¹¹, which excludes depreciation and amortization and share-based compensation expenses from operating profit, was RMB55.3 million (US$8.1 million) for the second quarter of 2026, compared with RMB26.6 million for the same period of 2025.

Group Financial Highlights

• Net revenue was RMB3,403.2 million (US$501.6 million) for the second quarter of 2026, compared with RMB3,578.0 million for the same period of 2025.
• Net profit was RMB426.8 million (US$62.9 million) for the second quarter of 2026, compared with RMB751.3 million for the same period of 2025.
• U.S. GAAP operating profit was RMB529.2 million (US$78.0 million) for the second quarter of 2026, compared with RMB815.5 million for the same period of 2025.
• Non-GAAP adjusted operating profit¹⁵, which excludes share-based compensation expenses before tax, was RMB572.1 million (US$84.3 million) for the second quarter of 2026, compared with RMB854.8 million for the same period of 2025.
• Diluted net profit per American depositary share (“ADS”) was RMB1.80 (US$0.26) and diluted net profit per share was RMB0.36 (US$0.05) for the second quarter of 2026, compared with RMB2.82 and RMB0.56 for the same period of 2025, respectively.
• Non-GAAP diluted net profit per ADS was RMB1.97 (US$0.29) and non-GAAP diluted net profit per share was RMB0.39 (US$0.06) for the second quarter of 2026, compared with RMB2.97 and RMB0.59 for the same period of 2025, respectively. Each ADS of the Company represents five Class A ordinary shares of the Company.

_________________________
1 Represents the total transaction volume facilitated in the Chinese Mainland and overseas markets on the Company’s platform during the period presented.
² Represents our transaction volume facilitated in the Chinese Mainland during the period presented. During the second quarter, RMB14.4 billion was facilitated under the capital-light model, for which the Company does not bear principal risk.
³ Represents our transaction volume facilitated in Indonesia, the Philippines and Australia during the period presented.
⁴ Outstanding loan balance as of any date refers to the balance of outstanding loans in the Chinese Mainland market excluding loans delinquent for more than 180 days from such date. As of June 30, 2026, RMB33.4 billion was facilitated under the capital-light model, for which the Company does not bear principal risk.
⁵ Outstanding loan balance as of any date refers to the balance of outstanding loans in Indonesia, the Philippines and Australia excluding loans delinquent for more than 30 days from such date.
⁶ Represents the total number of borrowers in the Chinese Mainland who successfully borrowed on the Company’s platform during the period presented.
⁷ Represents the transaction volume facilitated for borrowers who had historically completed a transaction on the Company’s platform in the Chinese Mainland during the period presented.
⁸ “90 day+ delinquency ratio” refers to the outstanding principal balance of loans, excluding loans facilitated under the capital-light model, that were 90 to 179 calendar days past due as a percentage of the total outstanding principal balance of loans, excluding loans facilitated under the capital-light model on the Company’s platform as of a specific date. Loans that originated outside the Chinese Mainland are not included in the calculation.
⁹ Represents revenue from the Chinese Mainland. Prior period segment results from the Chinese Mainland have been recast to conform to the current period presentation. Please refer to the “Selected Segment Information” tables at the end of this release for a breakdown by segment for the periods presented.
¹⁰ Please refer to the “Selected Segment Information” tables at the end of this release for reconciliation between Operating Segment Profit/(Loss) and GAAP operating profit.
¹¹ Please refer to the “Selected Segment Information” tables at the end of this release for reconciliation between GAAP operating profit and Non-GAAP adjusted EBITDA.
¹² Represents the total number of borrowers in Indonesia, the Philippines and Australia who successfully borrowed on the Company’s platforms during the period presented.
¹³ Represents the total number of new borrowers in Indonesia, the Philippines and Australia whose transactions were facilitated on the Company’s platforms during the period presented.
¹⁴ Represents revenue from overseas markets outside the Chinese Mainland, namely Indonesia, the Philippines, and Australia. Prior period segment results from overseas markets have been recast to conform to the current period presentation. Please refer to “Selected Segment Information” for a breakdown by segment for the periods presented.
¹⁵ Please refer to “UNAUDITED Reconciliation of GAAP and Non-GAAP Results” for reconciliation between GAAP and Non-GAAP adjusted operating profit.
¹⁶ The Company has reclassified certain items within its consolidated balance sheets for the first quarter of 2026, including amounts between Loans receivable and Accounts receivable. These balance sheet reclassifications also resulted in corresponding changes in the presentation of certain items in the consolidated statements of cash flows under the indirect method. The impact of these reclassifications has been reflected in the consolidated statements of cash flows for the six months ended June 30, 2026.

Mr. Tiezheng Li, Vice Chairman and Chief Executive Officer of FinVolution, commented, “Our second quarter results reflect a growing recovery following the risk mitigation actions we took in the second half of last year, with transaction volume, net revenue, and net profit all up sequentially. Both our Chinese Mainland and Overseas segments delivered resilient performances against an evolving regulatory and macro backdrop across several of our markets, reinforcing the value of our two-engine model.

“Asset quality in the Chinese Mainland segment remained solid, supported by the healthier borrower mix we captured during this year’s industry consolidation. Meanwhile, the Overseas segment continued to gain traction under our ‘Local Excellence, Global Outlook+’ strategy. Our unique borrower base more than doubled to 5.3 million, driving continued overall profitability across our international footprint, underscoring the growing earnings power of our diversified platform.

“As we enter the third quarter, we are navigating industry headwinds as institutional funding in China tightens at the moment coupled with an evolving risk environment. We intend to stay disciplined on origination rather than chase high-risk volume. Our dual-engine profitability, technology edge and healthy, low-leverage balance sheet give us the flexibility to manage this period while continuing to build long-term value for customers and shareholders,” concluded Mr. Li.

Mr. Jiayuan Xu, Chief Financial Officer of FinVolution, continued, “Total net revenues were RMB3.4 billion for the second quarter, up 6% sequentially, and net profit was RMB426.8 million, up 1% sequentially. The Chinese Mainland segment contributed RMB2.4 billion in revenue, up 8% sequentially. Overseas segment revenue was RMB930.3 million, up 18% year over year. Overseas operating profit more than doubled to RMB53.6 million, demonstrating sustained profitability across our international footprint.

“Our balance sheet remains robust, with RMB6.4 billion in cash and short-term investments, while our leverage ratio stands at 2.1x, around historic lows. We repurchased US$27.4 million in shares during the quarter, bringing our first-half 2026 total to US$66.8 million. Despite anticipated industry headwinds in the third quarter, we are maintaining our full-year revenue outlook of RMB11.5 billion to RMB12.9 billion. We remain committed to disciplined execution and to delivering sustainable, long-term value for our shareholders,” concluded Mr. Xu.

Second Quarter 2026 Financial Results

Net revenue for the second quarter of 2026 was RMB3,403.2 million (US$501.6 million), compared with RMB3,578.0 million for the same period of 2025. This decrease was primarily due to decreases in loan facilitation service fees, post-facilitation service fees and guarantee income, partially offset by increases in net interest income.

Loan facilitation service fees were RMB1,313.8 million (US$193.6 million) for the second quarter of 2026, compared with RMB1,515.3 million for the same period of 2025. The decrease was primarily due to decreases in transaction volume in the Chinese Mainland market, partially offset by the increase in transaction volume in overseas markets.

Post-facilitation service fees were RMB386.0 million (US$56.9 million) for the second quarter of 2026, compared with RMB425.6 million for the same period of 2025. This decrease was primarily due to the rolling impact of deferred transaction fees.

Guarantee income was RMB904.5 million (US$133.3 million) for the second quarter of 2026, compared with RMB1,046.6 million for the same period of 2025. This decrease was primarily due to the decrease in risk-bearing loans in the Chinese Mainland market, as well as the rolling impact of deferred guarantee income. The fair value of quality assurance commitment upon loan origination is released as guarantee income systematically over the term of the loans subject to quality assurance commitment.

Net interest income was RMB474.3 million (US$69.9 million) for the second quarter of 2026, compared with RMB272.1 million for the same period of 2025. This increase mainly resulted from the increase in the average outstanding loan balances of on-balance sheet loans in both the Chinese Mainland and overseas markets, partially offset by the decrease in interest yield in the Chinese Mainland market.

Other revenue was RMB324.6 million (US$47.8 million) for the second quarter of 2026, compared with RMB318.3 million for the same period of 2025. This increase was primarily due to the increase in the contributions from other revenue streams, including other value-added services.

Origination, servicing expenses and other costs of revenue were RMB732.9 million (US$108.0 million) for the second quarter of 2026, compared with RMB674.5 million for the same period of 2025. This increase was primarily driven by the increase in employee expenditures in both the Chinese Mainland and overseas markets, partially offset by the decrease in loan collection expenses in the Chinese Mainland market.

Sales and marketing expenses were RMB480.9 million (US$70.9 million) for the second quarter of 2026, compared with RMB606.4 million for the same period of 2025. This decrease was primarily due to improved efficiency and decreased investment in marketing activities in the Chinese Mainland market.

Research and development expenses were RMB118.9 million (US$17.5 million) for the second quarter of 2026, compared with RMB129.0 million for the same period of 2025. This decrease was primarily due to efficiency improvements in technology development.

General and administrative expenses were RMB106.3 million (US$15.7 million) for the second quarter of 2026, compared with RMB110.2 million for the same period of 2025. This decrease was primarily due to a decrease in professional services fees.

Provision for accounts receivable and contract assets was RMB97.9 million (US$14.4 million) for the second quarter of 2026, compared with RMB106.3 million for the same period of 2025. The decrease was primarily due to decreased transaction volume of off-balance sheet loans in the Chinese Mainland.

Provision for loans
receivable was RMB164.4 million (US$24.2 million) for the second quarter of 2026, compared with RMB98.4 million for the same period of 2025. This increase was primarily due to the increase in the outstanding loan balance of on-balance sheet loans in the Chinese Mainland and overseas markets.

Credit losses for quality assurance commitment were RMB1,108.8 million (US$163.4 million) for the second quarter of 2026, compared with RMB987.1 million for the same period of 2025. The increase was primarily due to the increase in risk-bearing loans in the overseas markets.

Impairment of goodwill and intangible assets was RMB63.8 million (US$9.4 million) for the second quarter of 2026, compared with RMB50.4 million for the same period of 2025. The impairment of intangible assets in 2026 was primarily due to an impairment of micro-lending licenses related to a certain micro-lending company acquired by the Group in 2017, following a performance review during the quarter.

Operating profit was RMB529.2 million (US$78.0 million) for the second quarter of 2026, compared with RMB815.5 million for the same period of 2025.

Non-GAAP adjusted operating profit, which excludes share-based compensation expenses before tax, was RMB572.1 million (US$84.3 million) for the second quarter of 2026, compared with RMB854.8 million for the same period of 2025.

Other income was RMB33.9 million (US$5.0 million) for the second quarter of 2026, compared with RMB115.9 million for the same period of 2025. The decrease was mainly due to an increase in foreign exchange losses and a decrease in government subsidies.

Income tax expense was RMB116.4 million (US$17.1 million) for the second quarter of 2026, compared with RMB178.7 million for the same period of 2025. This decrease was mainly due to the decrease in pre-tax profit.

Net profit was RMB426.8 million (US$62.9 million) for the second quarter of 2026, compared with RMB751.3 million for the same period of 2025.

Net profit attributable to ordinary shareholders of the Company was RMB441.6 million (US$65.1 million) for the second quarter of 2026, compared with RMB747.0 million for the same period of 2025.

Diluted net profit per ADS was RMB1.80 (US$0.26) and diluted net profit per share was RMB0.36 (US$0.05) for the second quarter of 2026, compared with RMB2.82 and RMB0.56 for the same period of 2025, respectively.

Non-GAAP diluted net profit per ADS was RMB1.97 (US$0.29) and non-GAAP diluted net profit per share was RMB0.39 (US$0.06) for the second quarter of 2026, compared with RMB2.97 and RMB0.59 for the same period of 2025, respectively. Each ADS represents five Class A ordinary shares of the Company.

As of June 30, 2026, the Company had cash and cash equivalents of RMB3,259.4 million (US$480.4 million) and short-term investments, mainly in wealth management products and term deposits, of RMB3,162.0 million (US$466.0 million).

The following chart shows the historical cumulative 30-day plus past due delinquency rates by loan origination vintage for loan products facilitated through the Company’s platform in the Chinese Mainland as of June 30, 2026. Loans facilitated under the capital-light model, for which the Company does not bear principal risk, are excluded from the chart.

Shares Repurchase Update

For the second quarter of 2026, the Company deployed approximately US$27.4 million to repurchase its own Class A ordinary shares in the form of ADSs. As of June 30, 2026, in combination with the Company’s historical and existing share repurchase programs, the Company had cumulatively repurchased its own Class A ordinary shares in the form of ADSs with a total aggregate value of approximately US$544.1 million since 2018.

Business Outlook

Looking ahead to the third quarter, we anticipate a considerable contraction in transaction volume in China, reflecting industry headwinds as institutional funding to the industry tightens at the moment. Despite this near-term impact, underpinned by the strength of our two-engine model and disciplined execution, we reiterate the Company’s full-year 2026 total revenue guidance to be in the range of approximately RMB11.5 billion to RMB12.9 billion.

The above forecast is based on the current market conditions and reflects the Company’s current preliminary views and expectations on market and operational conditions and the regulatory and operating environment, as well as customers’ and institutional partners’ demands, all of which are subject to change.

Conference Call

The Company’s management will host an earnings conference call at 8:30 PM U.S. Eastern Time on August 27, 2026 (8:30 AM Beijing/Hong Kong Time on August 28, 2026).

Participants should complete online registration using the link provided below at least 15 minutes before the scheduled start time. Upon registration, participants will receive the conference call access information, including dial-in numbers, a personal PIN and an e-mail with detailed instructions to join the conference call.

Participant Online Registration:
https://register-conf.media-server.com/register/BI0f0012327500446398832920fa161c5b

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.finvgroup.com.

About FinVolution Group

FinVolution Group is a leading fintech platform with strong brand recognition across China and overseas markets, connecting borrowers of the young generation with financial institutions. Established in 2007, the Company is a pioneer in China’s online consumer finance industry and has developed innovative technologies and accumulated in-depth experience in the core areas of credit risk assessment, fraud detection, big data and artificial intelligence. The Company’s platform, empowered by proprietary cutting-edge technologies, features a highly automated loan transaction process, which enables a superior user experience. As of June 30, 2026, the Company had 254.2 million cumulative registered users across China and overseas markets.

For more information, please visit https://ir.finvgroup.com

Use of Non-GAAP Financial Measures

We use non-GAAP adjusted operating profit, non-GAAP operating margin, non-GAAP adjusted EBITDA, non-GAAP net profit, non-GAAP net profit attributable to FinVolution Group, and non-GAAP basic and diluted net profit per share and per ADS which are non-GAAP financial measures, in evaluating our operating results and for financial and operational decision-making purposes. We believe that these non-GAAP financial measures help identify underlying trends in our business by excluding the impact of share-based compensation expenses and expected discretionary measures. We believe that non-GAAP financial measures provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

Non-GAAP adjusted operating profit, non-GAAP operating margin, non-GAAP adjusted EBITDA, non-GAAP net profit, non-GAAP net profit attributable to FinVolution Group, and non-GAAP basic and diluted net profit per share and per ADS are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. These non-GAAP financial measures have limitations as analytical tool, and when assessing our operating performance, cash flows or our liquidity, investors should not consider it in isolation, or as a substitute for net income, cash flows provided by operating activities or other consolidated statements of operation and cash flow data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review our financial information in its entirety and not rely on a single financial measure.

For more information on this non-GAAP financial measure, please see the table captioned “Reconciliations of GAAP and Non-GAAP results” set forth at the end of this press release.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.7851 to US$1.00, the rate in effect as of June 30, 2026 as certified for customs purposes by the Federal Reserve Bank of New York.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company’s ability to attract and retain borrowers and investors on its marketplace, its ability to increase volume of loans facilitated through the Company’s marketplace, its ability to introduce new loan products and platform enhancements, its ability to compete effectively, laws, regulations and governmental policies relating to the online consumer finance industry in China, general economic conditions in China, and the Company’s ability to meet the standards necessary to maintain listing of its ADSs on the NYSE, including its ability to cure any non-compliance with the NYSE’s continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and FinVolution does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For investor and media inquiries, please contact:

In China:
FinVolution Group
Head of Capital Markets
Yam Cheng
Tel: +86 (21) 8030-3200 Ext. 8601
E-mail: [email protected]

Piacente Financial Communications
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: [email protected]

In the United States:
Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected]

FinVolution Group UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (All amounts in thousands, except share data, or otherwise noted)
	As of December 31,		As of June 30,
	2025		2026
	RMB		RMB	USD
Assets
Cash and cash equivalents	4,285,121		3,259,378	480,373
Restricted cash	1,912,850		1,631,542	240,460
Short-term investments	3,015,226		3,161,992	466,020
Investments	1,141,816		1,164,822	171,674
Quality assurance receivable, net of credit loss allowance for quality assurance receivable of RMB581,475 and RMB666,160 as of December 31, 2025 and June 30, 2026, respectively	1,315,184		1,421,677	209,529
Intangible assets	270,246		206,483	30,432
Property, equipment and software, net	641,316		620,700	91,480
Loans receivable, net of credit loss allowance for loans receivable of RMB544,905 and RMB416,552 as of December 31, 2025 and June 30, 2026, respectively	6,471,619		6,597,360	972,331
Accounts receivable and contract assets, net of credit loss allowance for accounts receivable and contract assets of RMB340,816 and RMB286,557 as of December 31, 2025 and June 30, 2026, respectively	2,028,585		2,895,985	426,815
Deferred tax assets	2,992,071		3,504,367	516,480
Right of use assets	52,020		45,000	6,632
Prepaid expenses and other assets	1,207,791		1,484,090	218,728
Goodwill	79,759		79,759	11,755
Total assets	25,413,604		26,073,155	3,842,709
Deferred guarantee income	1,119,004		1,256,324	185,159
Liability from quality assurance commitment	2,574,842		2,684,907	395,706
Payroll and welfare payable	361,188		244,077	35,972
Taxes payable	177,064		477,073	70,312
Short-term borrowings	170,408		387,456	57,104
Funds payable to investors of consolidated trusts	778,531		739,575	109,000
Contract liability	226		–	–
Deferred tax liabilities	786,556		736,814	108,593
Accrued expenses and other liabilities	1,448,231		1,619,544	238,692
Leasing liabilities	44,711		40,061	5,904
Convertible senior notes	1,019,266		991,199	146,085
Long-term borrowings	89,590		155,789	22,960
Total liabilities	8,569,617		9,332,819	1,375,487
Commitments and contingencies
FinVolution Group Shareholders’ equity
Ordinary shares	103		103	15
Additional paid-in capital	5,908,586		5,986,830	882,350
Treasury stock	(2,465,259)		(2,831,861)	(417,365)
Statutory reserves	1,042,312		1,042,312	153,618
Accumulated other comprehensive income	13,027		32,870	4,846
Retained Earnings	12,051,332		12,401,237	1,827,716
Total FinVolution Group shareholders’ equity	16,550,101		16,631,491	2,451,180
Non-controlling interest	293,886		108,845	16,042
Total shareholders’ equity	16,843,987		16,740,336	2,467,222
Total liabilities and shareholders’ equity	25,413,604		26,073,155	3,842,709

FinVolution Group UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (All amounts in thousands, except share data, or otherwise noted)
	For the Three Months Ended June 30,					For the Six Months Ended June 30,
	2025		2026			2025		2026
	RMB		RMB	USD		RMB		RMB		USD
Operating revenue:
Loan facilitation service fees	1,515,349		1,313,757	193,624		2,993,147		2,495,071		367,728
Post-facilitation service fees	425,595		385,994	56,888		806,209		734,337		108,228
Guarantee income	1,046,615		904,520	133,310		2,146,129		1,790,589		263,900
Net interest income	272,098		474,296	69,903		513,712		958,977		141,336
Other revenue	318,294		324,602	47,840		599,795		634,257		93,478
Net revenue	3,577,951		3,403,169	501,565		7,058,992		6,613,231		974,670
Operating expenses:
Origination, servicing expenses and other cost of revenue	(674,544)		(732,912)	(108,018)		(1,295,009)		(1,478,084)		(217,843)
Sales and marketing expenses	(606,444)		(480,851)	(70,869)		(1,136,147)		(973,298)		(143,446)
Research and development expenses	(128,974)		(118,934)	(17,529)		(255,015)		(244,393)		(36,019)
General and administrative expenses	(110,196)		(106,349)	(15,674)		(217,090)		(220,192)		(32,452)
Provision for accounts receivable and contract assets	(106,345)		(97,868)	(14,424)		(224,063)		(209,382)		(30,859)
Provision for loans receivable	(98,379)		(164,435)	(24,235)		(183,793)		(382,583)		(56,386)
Credit losses for quality assurance commitment	(987,139)		(1,108,811)	(163,419)		(1,998,754)		(1,965,448)		(289,671)
Impairment of goodwill and intangible assets	(50,411)		(63,760)	(9,397)		(50,411)		(63,760)		(9,397)
Total operating expenses	(2,762,432)		(2,873,920)	(423,565)		(5,360,282)		(5,537,140)		(816,073)
Operating profit	815,519		529,249	78,000		1,698,710		1,076,091		158,597
Interest expenses	(1,444)		(20,018)	(2,950)		(2,096)		(37,165)		(5,477)
Other income, net	115,908		33,900	4,996		124,941		18,379		2,709
Profit before income tax expense	929,983		543,131	80,046		1,821,555		1,057,305		155,829
Income tax expenses	(178,670)		(116,361)	(17,149)		(332,601)		(209,478)		(30,873)
Net profit	751,313		426,770	62,897		1,488,954		847,827		124,956
Less: Net profit/(loss) attributable to non-controlling interest shareholders	4,316		(14,781)	(2,178)		(4,449)		(8,786)		(1,295)
Net profit attributable to FinVolution Group	746,997		441,551	65,075		1,493,403		856,613		126,251
Foreign currency translation adjustment, net of nil tax	705		(5,213)	(768)		(15,568)		19,843		2,924
Total comprehensive income attributable to FinVolution Group	747,702		436,338	64,307		1,477,835		876,456		129,175
Weighted average number of ordinary shares used in computing net profit per share
Basic	1,280,035,833		1,179,633,966	1,179,633,966		1,272,937,319		1,186,923,976		1,186,923,976
Diluted	1,322,804,429		1,252,313,020	1,252,313,020		1,319,415,709		1,268,035,160		1,268,035,160
Net profit per share attributable to FinVolution Group’s ordinary shareholders
Basic	0.58		0.37	0.06		1.17		0.72		0.11
Diluted	0.56		0.36	0.05		1.13		0.69		0.10
Net profit per ADS attributable to FinVolution Group’s ordinary shareholders (one ADS equals five ordinary shares)
Basic	2.92		1.87	0.28		5.87		3.61		0.53
Diluted	2.82		1.80	0.26		5.66		3.44		0.51

FinVolution Group UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (All amounts in thousands, except share data, or otherwise noted)
	Three Months Ended June 30,						Six Months Ended June 30,
	2025		2026				2025		2026
	RMB		RMB		USD		RMB		RMB		USD
Net cash provided by/(used in) operating activities	8,627		(389,983)		(57,477)		530,962		(805,354)		(118,695)
Net cash (used in)/ provided by investing activities	(1,025,083)		(515,472)		(75,971)		(659,887)		271,911		40,075
Net cash provided by/(used in) financing activities	658,029		(708,061)		(104,355)		459,698		(698,643)		(102,967)
Effect of exchange rate changes on cash and cash equivalents	5,754		(46,217)		(6,811)		(5,511)		(74,965)		(11,048)
Net increase in cash, cash equivalent and restricted cash	(352,673)		(1,659,733)		(244,614)		325,262		(1,307,051)		(192,635)
Cash, cash equivalent and restricted cash at beginning of period	7,425,007		6,550,653		965,447		6,747,072		6,197,971		913,468
Cash, cash equivalent and restricted cash at end of period	7,072,334		4,890,920		720,833		7,072,334		4,890,920		720,833

FinVolution Group UNAUDITED Reconciliation of GAAP and Non-GAAP Results  (All amounts in thousands, except share data, or otherwise noted)
	For the Three Months Ended June 30,					For the Six Months Ended June 30,
	2025		2026			2025		2026
	RMB		RMB	USD		RMB		RMB	USD
Net Revenues	3,577,951		3,403,169	501,565		7,058,992		6,613,231	974,670
Less: total operating expenses	(2,762,432)		(2,873,920)	(423,565)		(5,360,282)		(5,537,140)	(816,073)
Operating Profit	815,519		529,249	78,000		1,698,710		1,076,091	158,597
Add: share-based compensation expenses	39,318		42,866	6,318		73,997		81,039	11,944
Non-GAAP adjusted operating profit	854,837		572,115	84,318		1,772,707		1,157,130	170,541
Operating Margin	22.8%		15.6%	15.6%		24.1%		16.3%	16.3%
Non-GAAP operating margin	23.9%		16.8%	16.8%		25.1%		17.5%	17.5%
Non-GAAP adjusted operating profit	854,837		572,115	84,318		1,772,707		1,157,130	170,541
Less: interest expenses	(1,444)		(20,018)	(2,950)		(2,096)		(37,165)	(5,477)
Add: other income, net	115,908		33,900	4,996		124,941		18,379	2,709
Less: income tax expenses	(178,670)		(116,361)	(17,149)		(332,601)		(209,478)	(30,873)
Non-GAAP net profit	790,631		469,636	69,215		1,562,951		928,866	136,900
Less: Net profit/(loss) attributable to non-controlling interest shareholders	4,316		(14,781)	(2,178)		(4,449)		(8,786)	(1,295)
Non-GAAP net profit attributable to FinVolution Group	786,316		484,417	71,393		1,567,400		937,652	138,195
Weighted average number of ordinary shares used in computing net income per share
Basic	1,280,035,833		1,179,633,966	1,179,633,966		1,272,937,319		1,186,923,976	1,186,923,976
Diluted	1,322,804,429		1,252,313,020	1,252,313,020		1,319,415,709		1,268,035,160	1,268,035,160
Non-GAAP net profit per share attributable to FinVolution Group’s ordinary shareholders
Basic	0.61		0.41	0.06		1.23		0.79	0.12
Diluted	0.59		0.39	0.06		1.19		0.75	0.11
Non-GAAP net profit per ADS attributable to FinVolution Group’s ordinary shareholders (one ADS equal five ordinary shares)
Basic	3.07		2.05	0.30		6.16		3.95	0.58
Diluted	2.97		1.97	0.29		5.94		3.76	0.54

FinVolution Group Selected Segment Information (All amounts in thousands, except share data, or otherwise noted)
For the Three Months Ended June 30, 2026
	Chinese Mainland	Overseas Markets ( 1)	Others ( 2)	Elimination	Total
	RMB	RMB	RMB	RMB	RMB
Net Revenue	2,396,725	930,283	81,676	(5,515)	3,403,169
Less(3): Operating Expenses (4)	(1,771,964)	(876,648)	(124,197)	5,515	(2,767,294)
Operating Segment Profit/(Loss)	624,761	53,635	(42,521)	–	635,875
Less: Unallocated expenses(5)					(106,626)
Operating profit					529,249

For the Three Months Ended June 30, 2025
	Chinese Mainland	Overseas Markets ( 1)	Others ( 2)	Elimination	Total
	RMB	RMB	RMB	RMB	RMB
Net Revenue	2,781,295	788,680	11,248	(3,272)	3,577,951
Less(3): Operating Expenses (4)	(1,867,744)	(763,104)	(45,127)	3,272	(2,672,703)
Operating Segment Profit/(Loss)	913,551	25,576	(33,879)	–	905,248
Less: Unallocated expenses(5)					(89,729)
Operating profit					815,519

Notes:

(1): “Overseas Markets” includes Indonesia, the Philippines and Australia.
(2): “Others” includes a combination of multiple business activities that each does not meet the quantitative thresholds to qualify as reportable segments.
(3): The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.
(4): “Operating Expenses” includes Origination, servicing expenses and other costs of revenue, Sales and marketing expenses, General and administrative expenses, Research and development expenses, Credit losses for quality assurance commitment, Provision for loans receivable and Provision for accounts receivable and contract assets.
(5): Unallocated expenses are mainly related to share-based compensation, impairment of goodwill of prior acquisitions, and other miscellaneous items that are not allocated to segments. These expenses are excluded from segment results as they are not reviewed by the CODM as part of segment performance.

FinVolution Group Selected Segment Information (All amounts in thousands, except share data, or otherwise noted)
For the Three Months Ended June 30, 2026
	Chinese Mainland	Overseas Markets	Others	Unallocated expenses	Total
	RMB	RMB	RMB	RMB	RMB
Operating profit	624,761	53,635	(42,521)	(106,626)	529,249
Add: Depreciation and amortization	17,180	1,625	267	–	19,072
Add: Share-based compensation expenses	–	–	–	42,866	42,866
Non-GAAP Adjusted EBITDA	641,941	55,260	(42,254)	(63,760)	591,187

For the Three Months Ended June 30, 2025
	Chinese Mainland	Overseas Markets	Others	Unallocated expenses	Total
	RMB	RMB	RMB	RMB	RMB
Operating profit	913,551	25,576	(33,879)	(89,729)	815,519
Add: Depreciation and amortization	17,035	1,020	125	–	18,180
Add: Share-based compensation expenses	–	–	–	39,318	39,318
Non-GAAP Adjusted EBITDA	930,586	26,596	(33,754)	(50,411)	873,017

Note:

“Non-GAAP Adjusted EBITDA” represents operating profit (loss) plus (a) depreciation and amortization expenses and (b) share-based compensation expenses.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cfab4379-0d6d-4261-a793-ffb1dbcfa6c2

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI^® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.

“This supplemental submission to ANVISA marks an important step in our efforts to expand MINJUVI^®’s potential in earlier lines of therapy in Brazil,” said Samira Sakhia, President and Chief Executive Officer of Knight. “Patients with previously untreated DLBCL and HGBL continue to face significant unmet medical needs. We are encouraged by the clinical data supporting the addition of tafasitamab and look forward to working with regulators under Project Orbis to bring this potential new first-line treatment option to patients as quickly as possible.”

In September 2021, Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (commercialized as MONJUVI^® in the United States and MINJUVI^® ex-U.S.). Knight has launched MINJUVI^® in Brazil, Mexico and Argentina for use in combination with lenalidomide, followed by MINJUVI^® monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL, who are not eligible for autologous stem cell transplantation (ASCT). In March 2026, Knight announced the approval and launch of MINJUVI^® in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) in Brazil.¹ Also in March 2026, Knight submitted MINJUVI^® for the same indication in Argentina and Mexico.

This supplemental submission to ANVISA builds on those approvals, seeking a first-line indication for MINJUVI^® based on results from the Phase 3 frontMIND trial.

About MINJUVI
^®

MINJUVI^® (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb^® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.

In the U.S., MONJUVI^® is approved for use in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).²

Additionally, MONJUVI^® received approval in the U.S. in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).² This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Europe, MINJUVI^® received conditional marketing authorization from the European Medicines Agency in combination with lenalidomide, followed by MINJUVI^®monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. Additionally, MINJUVI^® is approved for use in Europe in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory FL (Grade 1-3a) after at least one line of systemic therapy.³

In Japan, MINJUVI^® is approved for use in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).⁴ MINJUVI^® is also approved for use in Japan in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory FL (2L+ FL).⁵

XmAb is a registered trademark of Xencor, Inc.

MONJUVI^® and MINJUVI^® are registered trademarks of Incyte. All other trademarks are the property of their respective owners.

About
Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults worldwide, accounting for a third of all NHLs and ranging between 20%−50% by country.⁶ DLBCL commonly presents with enlarged lymph nodes or rapidly growing mass along with B symptoms, which include fever, night sweats, and weight loss. The B symptoms can be seen in 30% of patients. Bone marrow involvement is more common in indolent disease and can be seen in up to 50% of the cases.⁷ Each year, approximately 25,000 people in the U.S. and up to projected 28,000 people in Western Europe are diagnosed with DLBCL.^8,9 In Brazil, data from The Department of Information Technology of the Brazilian Public Unified Healthcare System (DataSUS) reported DLBCL as the most frequently diagnosed NHL with 39,012 cases reported between 2008 – 2017. With about 40% of DLBCL patients not responding to initial therapy or relapsing thereafter,^10,11 there is a high medical need for new, effective therapies, particularly for high-risk patients.

About High-grade B-Cell Lymphoma (HGBL)

High-grade B-Cell Lymphoma (HGBL) is a rare and aggressive category of B-cell non-Hodgkin lymphoma (NHL) defined by the World Health Organization (WHO).¹² It comprises two principal subtypes based on specific genetic characteristics: DLBCL/HGBL with MYC and BCL2 rearrangements, which encompasses most lymphomas previously known as double- or triple-hit lymphoma, and HGBL, not otherwise specified (NOS), a heterogeneous subtype defined by high-grade morphology in the absence of these genetic rearrangements.^12,14 HGBL shares clinical features with DLBCL, including rapidly enlarging lymph nodes and B symptoms such as fever, night sweats, and weight loss, and accurate diagnosis requires expert pathologic review incorporating cytomorphology, immunohistochemistry, and fluorescence in situ hybridization (FISH).^12,15 The aggressive nature of HGBL and the failure of intensified therapy to improve overall survival underscore the significant unmet need for more effective treatment options.^12,13

About frontMIND trial

The frontMIND trial (NCT04824092) is a randomized, double-blind, placebo-controlled, global Phase 3 study in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).¹⁶

The study enrolled 899 adults (≥18 to ≤80 years) and is evaluating the efficacy and safety of tafasitamab and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared with R-CHOP.¹⁶

The primary endpoint of the study is investigator-assessed progression-free survival (PFS) using the Lugano 2014 criteria. Key secondary endpoints include event-free survival (EFS) by investigator assessment and overall survival (OS).¹⁶

For more information about the frontMIND trial, please visit https://www.clinicaltrials.gov/study/NCT04824092.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at https://knighttx.com/ or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. MINJUVI (tafasitamab) Powder for solution for infusion 200 mg ANVISA; prescribing information January, 2026. Accessed February 19th 2026.
2. MONJUVI (tafasitamab-cxix) [package insert]. Wilmington, DE: Incyte Corporation; June, 2025. Accessed June 8, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761163s013lbl.pdf
3. Minjuvi (tafasitamab) [summary of product characteristics]. Amsterdam, the Netherlands: Incyte Biosciences Distribution B.V.; January, 2026. Accessed June 8, 2026. https://www.ema.europa.eu/en/documents/product-information/minjuvi-epar-product-information_en.pdf
4. Incyte. Minjuvi^® (tafasitamab) Product Information (Japan) and Pharmaceuticals and Medical Devices Agency (PMDA) electronic package insert. Accessed June 2026. https://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html.
5. Biosciences Japan G.K. Incyte Japan announces approval of Minjuvi^® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Incyte. Published June 19, 2026. Accessed July 30, 2026. https://investor.incyte.com/news-releases/news-release-details/incyte-japan-announces-approval-minjuvir-tafasitamab-0
6. Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):255-266. doi:10.1053/j.seminhematol.2023.11.004
7. Padala SA, Kallam A. Diffuse large B-cell lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated April 24, 2023. Accessed June 8, 2026. https://www.ncbi.nlm.nih.gov/books/NBK557796/
8. Chihara D, Johnston K, Bolatova T, et al. An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2022;22(12):e1092-e1099. doi:10.1016/j.clml.2022.08.008
9. Berhan A, Almaw A, Damtie S, Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Oncol. 2025;16(1):184. Published 2025 Feb 15. doi:10.1007/s12672-025-01958-w
10. Martins DP, Correa-Netto NF, Melo N, Loggetto SR, de Liberal MMC. Overview of lymphoma diagnosis in Brazilian public health system patients: Open data analysis for health care planning. Hematol Transfus Cell Ther. 2022;44(1):40-48. doi:10.1016/j.htct.2020.08.017
11. Sawalha Y. Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. J Pers Med. 2021;11(12):1345. Published 2021 Dec 10. doi:10.3390/jpm11121345
12. Lymphoma Research Foundation. High-grade B-cell lymphoma. Updated May 2024. Accessed June 19, 2026. https://lymphoma.org/publication/high-grade-b-cell-lymphoma-fact-sheet/
13. Davies AJ. The high-grade B-cell lymphomas: double hit and more. Blood. 2024;144(25):2583-2592. doi:10.1182/blood.2023020780
14. Zayac AS, Landsburg DJ, Hughes ME, et al. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv. 2023;7(21):6381-6394. doi:10.1182/bloodadvances.2023009731
15. Olszewski AJ, Avigdor A, Bachy E, et al. Defining and treating high-grade B-cell lymphoma, NOS. Blood. 2022;140(9):943-954. doi:10.1182/blood.2022016534
16. Lenz G, Trněný M, Burke JM, et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. Published online May 30, 2026. doi:10.1016/S0140-6736(26)00866-4

CONTACT INFORMATION:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T. 514.484.4483
Email: [email protected]	Email: [email protected]
Website: www.knighttx.com	Website: www.knighttx.com